ORIGINAL PAPER



Psychosocial Impact of COVID-19 Pandemic in Elderly Psychiatric Patients: a Longitudinal Study

Magdalena Seethaler¹ · Sandra Just¹ · Philip Stötzner¹ · Felix Bermpohl¹ · Eva Janina Brandl¹

Accepted: 4 April 2021 / Published online: 26 April 2021 © The Author(s) 2021

Abstract

The study was designed to investigate the impact of the Coronavirus Disease 2019 (COVID-19) pandemic on mental health and perceived psychosocial support for elderly psychiatric patients in a longitudinal design. n=32 patients with affective or anxiety disorders aged ≥ 60 years were included. Telephone interviews were conducted in April/May 2020 (T1) and August 2020 (T2). The psychosocial impact (PSI) of the pandemic and psychopathology were measured. Changes between T1 and T2 were examined. Patients' psychosocial support system six months before the pandemic and at T1/T2 was assessed. We found a significant positive correlation between general PSI and depression as well as severity of illness. General PSI differed significantly depending on social contact. Neither general PSI nor psychopathology changed significantly between T1 and T2. At T1, patients' psychosocial support systems were reduced as compared to six months before. Patients reported an increase in psychosocial support between T1 and T2 and high demand for additional support (sports, arts/occupational therapy, physiotherapy, psychotherapy). Elderly psychiatric patients show a negative PSI of the pandemic. They are likely to suffer from an impaired psychosocial situation, emphasizing the importance of developing concepts for sufficient psychosocial support during a pandemic.

Keywords COVID-19 \cdot Elderly \cdot Geriatric psychiatry \cdot Mental health \cdot Psychosocial burden \cdot Depression

Abbreviations

COVID-19	Coronavirus Disease-2019
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
ICU	Intensive Care Unit
MERS-CoV	Middle East Respiratory Syndrome-related Coronavirus

Magdalena Seethaler and Sandra Just contributed equally to this work.

Magdalena Seethaler magdalena.seethaler@charite.de

¹ Department of Psychiatry and Psychotherapy, Campus Charité Mitte (Psychiatric University Clinic at St. Hedwig Hospital), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

PTSD	Posttraumatic Stress Disorder
PSI	Psychosocial Impact
DSM-5	Diagnostic and Statistical Manual of Mental Disorders
GDS-15	German Geriatric Depression Scale
OCD	Obsessive-Compulsive Disorder
CGI	Clinical Global Impression – Severity Scale

Introduction

Since the beginning of the Coronavirus Disease 2019 (COVID-19) pandemic in December 2019 in Wuhan, China, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide [1]. The overall cumulative hospitalization rate is described as 193.7 per 100,000, increasing to between 329.4 and 884.8 per 100,000 in people 65 years [2], who are considered a high-risk population [3].

Globally, more than one third of all COVID-19 patients were admitted to intensive care units (ICU) [4]. Older age was shown to be a risk factor for lethal course of COVID-19 [5]. Mortality increases to 14.8% to 28.7% in patients aged 80 years or older compared to an overall rate of 2.29% to 5.4% [3, 6].

Within a short period, SARS-CoV-2 has had an enormous impact on the world's societies, health systems and economy. Policies such as movement restrictions, social distancing and isolation and the hazard and consequences of getting infected with SARS-CoV-2 are likely to impact mental health, as this has been found for past epidemics/pandemics, such as the Spanish flu, Ebola or the Middle East Respiratory Syndrome-related Coronavirus (MERS-CoV) outbreak in 2015 [7–12].

The current COVID-19 pandemic may entail similar or even more serious consequences [13, 14]. SARS-CoV-2 has caused more than 2.5 million deaths as of March 2021 and is still spreading and accelerating [1] – heading towards far-reaching repercussions.

Negative psychosocial effects of the COVID-19 pandemic and social distancing measures, including general distress, traumatization, anxiety and depression were reported [15–17].

Several studies have examined mental health of vulnerable populations during the pandemic, such as health workers or SARS-CoV-2 patients [18, 19]. Among health workers in China and Singapore, elevated symptoms of anxiety [20–22], stress [20–22], Posttraumatic Stress Disorder (PTSD) [22, 23], depression [21, 22] were reported. One previous study found a negative psychological impact of the COVID-19 pandemic on the general elderly population in the US [24].

To our knowledge, there are no studies specifically examining the psychosocial impact (PSI) of the pandemic in elderly patients with pre-existing mental disorders. Especially the elderly are vulnerable and prone to showing severe illness from SARS-CoV-2 and its sequelae due to age and health conditions [25] and therefore being advised to follow precautionary measures such as highly restrictive social distancing [26]. Furthermore, for elderly people with an affective or anxiety disorder, fear of infection combined with reduction of social contacts (private and professional) might cause exacerbation of symptoms.

In this study, we systematically evaluated the impact of the COVID-19 pandemic on mental health of elderly patients with affective or anxiety disorders, investigating 1) sociodemographic and clinical information, 2) psychosocial impact of the COVID-19 pandemic, 3) psychopathology and 4) psychosocial support.

Methods

Participants

Sixty-eight patients were invited with a letter containing the study information and consent forms. In telephone calls, further information regarding the study was provided by the first authors. Thirty-three individuals provided written consent to participate. Reasons to refrain from participation included unstable mental health, hospitalization, and lack of interest in participation. n=32 participants were finally included at T1 and n=24 at T2 (see Table 1 for detailed sample characteristics). All participants were current or former patients of the Psychiatric University Hospital of Charité at St. Hedwig Hospital, Berlin, Germany. Participants were: (1) inpatients or outpatients with a main diagnosis of affective or anxiety disorder according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) confirmed by trained clinicians; (2) showed native proficiency in German language; (3) showed no severe cognitive impairment; (4) were ≥ 60 years old. The study was approved by the local ethics committee and followed the principles of the Declaration of Helsinki. The work was conducted taking into consideration principles for research involving humans, such as the aim to increase knowledge, a given necessity, the expectation of benefits and a voluntarily consent by patients after providing suitable information [27].

Study Design

A longitudinal design with two measurement points was chosen since our study strives for a better understanding of potential long-term pandemic-related impairment of psychiatric conditions as well as patients' psychosocial support system.

At the first measurement point T1 in April/May 2020, in Germany, schools and other institutions were closed and visits to hospitals/nursing homes were limited [28]. Further, many outpatient departments offered none or only digital appointments instead of face-to-face contacts. Especially for the elderly, this may have been challenging due to limited knowledge of and access to digital media [29]. Also, elderly patients often suffer from loneliness [30] and are more dependent on efficient care. Therefore, we expected to find a substantial negative PSI of the pandemic among elderly psychiatric patients at T1. The second measurement point T2 was scheduled three months after T1, in August 2020, to assess potential changes in PSI and psychopathology as well as patients' private and professional support system.

We hypothesized that PSI may be reduced at T2 due to decreased infection numbers and restrictions and habituation to the pandemic situation after a "first wave". Alternatively, considering the duration of 4 to 5 months of the pandemic with presumably ongoing containment measures or even facing a further escalated pandemic situation in Germany in August 2020, we assumed to find an increased PSI and overall deterioration of the psychosocial situation of elderly psychiatric patients.

Procedure

Interviews with a duration of approximately 20 min were conducted via telephone by trained clinicians. T1 baseline interviews took place in April and May 2020. T2 was set in August 2020, over a period of 27 days.

Variables		n (%) T1/T2
Number of patients		32/24
Age		
	Minimum	60
	Maximum	93
	Mean \pm Standard deviation	$77,94 \pm 8,12/78.25 \pm 8.43$
Sex		
	Female	20 (62.5%)/16 (66.67%)
	Male	12 (37.5%)/8 (33.33%)
Income		
	Pension	27 (84.38%)/20 (83.33%)
	Sick leave	1 (3.13%)/0
	Looking for work	2 (6.25%)/2 (8.33%)
	Other	2 (6.25%)/2 (8.33%)
Living situation		
	Rent	20 (62.5%)/18 (75%)
	Own property	4 (12.5%)/1 (4.2%)
	Nursing home	4 (12.5%)/2 (8.3%)
	Assisted living	1 (3.13%)/1 (4.2%)
	Other	2 (6.25%)/2 (8.3%)
	No information	1 (3.13%)/0 (0%)
Relationship status		
	None	8 (25%)/6 (25%)
	Married	9 (28.13%)/7 (29.2%)
	Widowed	8 (25%)/7 (29.2%)
	Divorced/separated	7 (21.88%)/4 (16.7%)
Household		
	Alone	17 (53.13%)/12 (50%)
	With partner	9 (28.13%)/6 (25%)
	With other relatives	1 (3.13%)/2 (8.3%)
	With multiple different relatives	5 (15.63%)/3 (12.5%)
	Assisted living	0 (0%)/1 (4.2%)
Social contact		
	Close	9 (28.13%)/7 (29.2%)
	Regularly	13 (40.63%)/10 (41.7%)
	Rarely	10 (31.25%)/7 (29.2%)

Table 1 Sociodemographic data

Measures

The structured interview consisted of five topics: 1) *sociodemographic and medical information*, including rating of social contact behavior on a scale from 0 (no contact) to 4 (close contact). 2.a) *psychosocial impact of the COVID-19 pandemic* was assessed using a questionnaire with 15 items (see Table 3) developed for this study, where participants rated the impact of the pandemic on several aspects from 0 (does not apply) to 5 (extremely high negative impact). 2.b) Additional open questions asking about what bothered participants most about the pandemic. 3) For *psychopathology*, depressive

symptoms in the last two weeks (yes/no format) were assessed with the 15-item version of the German Geriatric Depression Scale (GDS-15) [31]. The GDS-15 has shown good psychometric criteria [32, 33] and its German version has been used in clinical research [34]. Scores range from 0 (no depression) to 15 (severe depression), a cut-off \geq 5 is recommended [35]. Additional questions about general psychopathology included assessment of suicidality, anxiety, obsessive-compulsive disorder (OCD) and psychotic symptoms as well as substance abuse/addiction utilizing open questions according to the AMDP system [36]. Lifetime/current suicidality was rated as 1 (none), 2 (suicidal thoughts), 3 (suicidal plans), and 4 (suicidal attempt). Other psychopathology was assessed as 0 (none) or present (1). Severity of illness was assessed with the Clinical Global Impression – Severity Scale (CGI) [37] from 1 (not at all ill) to 7 (extremely severely ill). 4) Questions concerning *psychosocial support* asked whether participants received certain psychosocial support (see Table 4) in the six months prior to the pandemic (at T1) or since T1 (at T2) or were currently receiving them. If not, it was asked whether this was due to the pandemic and whether they wished to receive this form of support.

Statistical Analysis

Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 26.0 (Armonk, NY: IBM Corp.). Descriptive statistics and percentages were determined for all outcome variables. For group comparisons, assumptions for parametric tests were examined (normality as assessed by the Shapiro-Wilk-test and visual examination regarding outliers and distribution). Group differences were assessed using Kruskal-Wallis-tests, while analyses of differences between two groups were *t*-tests, Mann-Whitney *U* tests or χ^2 -tests. Dunn-Bonferroni multiple comparison correction was conducted. Paired tests were computed to compare scores in main outcome variables between T1 and T2, either using paired *t*-tests, Wilcoxon-signed-rank-test or McNemar's test. Pearson product-moment correlation coefficients were computed to assess the relationship between psychological impact of the pandemic and other outcome variables. *P*-values below *p* < 0.05 were considered significant.

Results

Sample Characteristics

Sociodemographic characteristics of the sample both at T1 and T2 are presented in Table 1. There were no significant differences in characteristics between dropouts and non-dropouts – however, several patients explained dropping out with a high psychosocial burden of the COVID-19 pandemic itself.

None of the participants reported a SARS-CoV-2 infection or quarantine stay from six months before the start of the study until T2.

A significant life event since T1 was reported by n=10 patients at T2. n=3 patients underwent major surgery and n=2 reported severe suicidal thoughts, one of them tried to commit suicide and was admitted to an inpatient facility. n=5 patients reported other challenges.

Clinical characteristics and psychopathology are portrayed in Table 2.

Psychosocial Impact

Mean PSI values were calculated for each question of the questionnaire, presented graphically for general PSI in Fig. 1 (item 1: "How negatively impacted have you felt in the last two weeks generally due to the COVID-19 pandemic?").

Three patient groups were formed depending on patients' social contact behavior at T1: n=9 patients (28.13%) reported close social contact, n=13 patients (40.63%) regular and n=10 patients (31.25%) rare social contact.

At T1, a significant difference in general PSI values between patients with close (Mdn=4.00), regular (Mdn=3.00) and rare social contact (Mdn=3.00; H(2)=6.366; p=.041) was found. Dunn-Bonferroni post-hoc analysis revealed a significantly higher general PSI in patients with close as compared to regular social contact (p=.013). At T2, no significant difference in general PSI values between patients with close (Mdn=3.00), regular (Mdn=3.00) and rare social contact (Mdn=3.00; H(2)=1.038; p=.595) was shown. PSI values were lowest in patients with regular social contact at T1 as well as T2.

At T1, there was a significant positive correlation between general PSI and GDS-15 sum scores (r(30) = .384, p = .030) and between general PSI and CGI values (r(30) = .376, p = .034). While these correlation coefficients were non-significant at T2, several other significant correlations were found between psychosocial impact and other outcome variables. Table 3 gives an overview of correlation coefficients at T1 and T2 between the 15 PSI items and the outcome variables: GDS-15 sum score, CGI value, current suicidality and social contact behavior.

Changes between T1 and T2

Comparing results of the PSI questionnaire at T1 and T2 revealed that the negative PSI due to lockdown restrictions was significantly higher at T1 (M=2.46; SD=1.82) as compared to T2 (M=1.42; SD=1.86), t(23)=2.389, p=.025. The negative PSI due to difficulties in shopping for goods other than daily necessities was significantly higher at T1 (M=1.88; SD=1.68) as compared to T2 (M=.96; SD=1.49), t(23)=2.298, p=.031. All other differences in PSI between T1 and T2 were not significant. Changes in other outcome variables between T1 and T2 were also not significant. For CGI severity of illness, at T1 and T2, a minimum of 1 and a maximum of 6 was observed (T1: $M=3.16\pm1.59$; T2: $M=3.00\pm1.41$; p=.868). The GDS-15 revealed a minimum of 1 and a maximum of 12 (T1) and 11 (T2) points (T1: $M=5.66\pm3.48$; T2: $M=5.50\pm3.62$; p=.809).

Current suicidal thoughts at T1 were reported by n=11 patients (34.38%). Among patients with suicidal thoughts at T1, around half (n=6) indicated that suicidality had developed or worsened over the last two weeks. At T2, n=4 (16.7%) patients reported suicidal thoughts, while one patient had suicidal plans and another patient had a suicidal attempt. Patients with a history of suicidality were thoroughly questioned regarding current suicidal ideation. The need for further diagnostic was evaluated and – in case of necessity – the access to therapeutic interventions or acute treatment was ensured.

Psychosocial Support

In the six months before the COVID-19 pandemic, all but one participant (n=31) reported receiving some kind of psychosocial support. The most frequently used sup-

Table 2 Psychopathology and Clinical Data

Main diagnosis Depressive Episode (F32) 5 (15.63%) Recurrent Depressive Disorder (F33) 20 (62.5%) Anxiety Disorder (F4) 3 (9.38%) Bipolar Affective Disorder (F31) 3 (9.38%) Persistent Affective Disorder (F34) 1 (3.13%) Secondary diagnosis 13 (40.63%) Somatic diagnosis 28 (87.5%) With somatic diagnosis 2 (6.26%) No information 2 (6.26%) Medication 13 (40.63%) Antidepressant 13 (40.63%) Antidepressant and antipsychotic 4 (12.5%) Antidepressant and other 4 (12.5%) Antidepressant and other 4 (12.5%) Antidepressant and other 4 (12.5%) Other 3 (9.38%) Change in last 2 weeks 9 (28.13%) No change in last 2 weeks 9 (28.13%) No tharge in last 2 weeks 9 (26.26%) CGI Minimum 1 Maximum 6 3.16 \pm 1.59/3.00 \pm 1.41 GDS sum 1 1 Maximum 12/11 Mean \pm Standar	Variables		n (%) T1/T2
PerformantDepressive Episode (F32)5 (15.63%)Recurrent Depressive Disorder (F33)20 (62.5%)Anxiety Disorder (F4)3 (9.38%)Bipolar Affective Disorder (F31)3 (9.38%)Secondary diagnosis1 (3.13%)Secondary diagnosis3 (40.63%)Somatic diagnosis2 (6.26%)Metication2 (6.26%)Medication2 (6.26%)Medication2 (6.25%)Antidepressant and antipsychotic4 (12.5%)Antidepressant and antipsychotic4 (12.5%)Antidepressant and antipsychotic and other4 (12.5%)Antidepressant and antipsychotic and other4 (12.5%)Antidepressant and antipsychotic and other4 (12.5%)Antidepressant and pressant and other4 (12.5%)Antidepressant and pressant and other4 (12.5%)Antidepressant and pressant and other4 (12.5%)Antidepressant and other4 (12.5%)Antidepressant and pressant and pressant and antipsychotic and other4 (12.5%)Antidepressant and pressant and pressant and antipsychotic and other4 (12.5%)Antidepressant and pressant and pressant and antipsychotic and other4 (12.5%)Antidepressant and pressant and pressant and antipsychotic and other4 (12.5%)CGIMinimum1Maximum61Adamut12/11Maximum12/11Adamut13 (40.63%)/10 (41.67%)AnxietyYes13 (40.63%)/10 (41.67%)AnxietyYes13 (40.63%)/10 (41.67%)AttemptsAttemp	Main diagnosis		
Recurrent Depressive Disorder (F33)20 (62.5%)Anxiety Disorder (F4)3 (9.38%)Bipolar Affective Disorder (F31)3 (9.38%)Persistent Affective Disorder (F34)1 (3.13%)Secondary diagnosis1 (3.13%)Somatic diagnosis28 (87.5%)Somatic diagnosis28 (87.5%)Mithout somatic diagnosis2 (6.26%)No information2 (6.26%)Medication1 (3.10,63%)Medication3 (40.63%)Antidepressant and antipsychotic4 (12.5%)Antidepressant and antipsychotic and other4 (12.5%)Antidepressant, antipsychotic and other4 (12.5%)Other3 (9.38%)Change in last 2 weeks9 (28.13%)No change in last 2 weeks9 (28.13%)CGIMinimum1Maximum6GDS sum1GDS sum1Minimum1Maximum13 (40.63%)/14 (58.33%)No13 (40.63%)/14 (58.33%)AnxietyYesNo13 (40.63%)/14 (58.33%)Lifetime suicidalityNeverPlans4 (12.5%)No11 (34.38%)Plans4 (12.5%)SuicidalityNoPlans4 (12.5%)Plans4 (12.5%)Plans1 (34.38%)/14 (56.7%)Plans4 (12.5%)Plans4 (12.5%)Plans4 (12.5%)Plans4 (12.5%)Plans1 (34.38%)/14 (16.67%)Plans0 (0/1 (4.17)		Depressive Episode (F32)	5 (15.63%)
Anxiety Disorder (F4)3 (9.38%)Bipolar Affective Disorder (F31)3 (9.38%)Bipolar Affective Disorder (F31)1 (3.13%)Secondary diagnosis1 (3.13%)Somatic diagnosis28 (87.5%)Somatic diagnosis28 (87.5%)With somatic diagnosis2 (6.26%)No information2 (6.26%)Medication2 (6.25%)Antidepressant and antipsychotic3 (40.63%)Antidepressant and antipsychotic4 (12.5%)Antidepressant and other4 (12.5%)Antidepressant, antipsychotic and other4 (12.5%)Other3 (9.38%)Change in last 2 weeks9 (28.13%)No change in last 2 weeks11 (65.63%)CGI1Minimum1Maximum2 (6.26%)Anxiety9 (99.38%)/14 (88.33%)GDS sum1Itimum1Maximum1Anxiety9 (95.938%)/14 (88.33%)No13 (40.63%)/10 (41.67%)Lifetime suicidalityNeverItagins1 (34.38%)/10 (41.67%)SuicidalityNoPlans0 (0/1 (4.17)		Recurrent Depressive Disorder (F33)	20 (62.5%)
Bipolar Affective Disorder (F31)3 (9.38%)Persistent Affective Disorder (F34)1 (3.13%)Secondary diagnosis13 (40.63%)Somatic diagnosis28 (87.5%)With somatic diagnosis2 (6.26%)No information2 (6.26%)Medication13 (40.63%)Medication2 (6.25%)Antidepressant and antipsychotic4 (12.5%)Antidepressant and other4 (12.5%)Antidepressant and other4 (12.5%)Other3 (9.38%)Change in last 2 weeks9 (28.13%)No change in last 2 weeks2 (6.26%)CGI11 (MinimumMaximum6Maximum1.6GDS sum11 (MinimumGDS sum12 (11Minimum1Maximum1.6AnxietyYesNo13 (40.63%)/14 (58.33%)Anxiety10 (NoAnxiety13 (40.63%)/14 (58.33%)Anxiety13 (40.63%)/14 (58.33%)Anxiety10 (34.38%)/14 (58.33%)Anxiety10 (34.38%)/14 (56.3%)/18 (75%)SuicidalityNo1 (45.5%)/18 (75%)SuicidalityNo1 (65.63%)/18 (75%)SuicidalityNo1 (65.63%)/18 (75%)Plans1 (34.38%)/4 (16.67%)Plans1 (34.		Anxiety Disorder (F4)	3 (9.38%)
Persistent Affective Disorder (F34)1 (3.13%)Secondary diagnosis13 (40.63%)Somatic diagnosis13 (40.63%)Somatic diagnosis2 (6.26%)Without somatic diagnosis2 (6.26%)No information2 (6.26%)Medication13 (40.63%)Antidepressant13 (40.63%)Antidepressant and antipsychotic2 (6.25%)Antidepressant and antipsychotic4 (12.5%)Antidepressant and other4 (12.5%)Other3 (9.38%)Charge in last 2 weeks9 (28.13%)No change in last 2 weeks21 (65.63%)Without medication2 (6.26%)CGI1Maximum6Maximum6Maximum1.159/3.00±1.41GDS sum1/1Minimum1Maximum1/1AnxietyYesNo13 (40.63%/10 (41.67%)Lifetime suicidalityNeverInoughts11 (34.38%)Plans4 (12.5%)SuicidalityNoNo11 (34.38%)Plans11 (34.38%)4 (16.67%)Plans11 (34.38%)4 (16.67%)		Bipolar Affective Disorder (F31)	3 (9.38%)
Secondary diagnosis13 (40.63%)Somatic diagnosis28 (87.5%)With somatic diagnosis2 (6.26%)Wethout somatic diagnosis2 (6.26%)No information2 (6.26%)Medication13 (40.63%)Antidepressant and antipsychotic4 (12.5%)Antidepressant and antipsychotic4 (12.5%)Antidepressant and other4 (12.5%)Antidepressant and other4 (12.5%)Other3 (9.38%)Charge in last 2 weeks9 (28.13%)No charge in last 2 weeks9 (28.13%)Kithout medication2 (6.26%)CGIInfimumMaximum6Maximum1Maximum1GDS sumInfinimumFiniteInfinimumMinimum1Maximum12/11Maximum13 (40.63%)/10 (41.67%)Lifetime suicidalityNeverInoughts11 (34.38%)No11 (34.38%)No11 (34.38%)Plans4 (12.5%)Noinghts11 (34.38%)/4 (16.67%)SuicidalityNoNo21 (65.63%)/18 (75%)Nonghts11 (34.38%)/4 (16.67%)SuicidalityNoNo21 (65.63%)/18 (75%)Nonghts11 (34.38%)/4 (16.67%)Name11 (34.38%)/4 (16.67%)Name11 (34.38%)/4 (16.67%)Name11 (34.38%)/4 (16.67%)Name11 (34.38%)/4 (16.67%)Name11 (34.38%)/4 (16.67%)Name11 (34.38%)/4 (16.67%)<		Persistent Affective Disorder (F34)	1 (3.13%)
Somatic diagnosisUith somatic diagnosis28 (87.5%)Without somatic diagnosis2 (6.26%)No information2 (6.26%)Medication13 (40.63%)Antidepressant13 (40.63%)Antidepressant and antipsychotic4 (12.5%)Antidepressant and antipsychotic4 (12.5%)Antidepressant, antipsychotic and other4 (12.5%)Other3 (9.38%)Change in last 2 weeks9 (28.13%)No change in last 2 weeks9 (28.13%)No change in last 2 weeks21 (65.63%)Maximum6Maximum1Maximum1Adximum6Maximum1.159/3.00±1.41GDS sum12/11Kanimum1Minimum1Maximum266±3.48/5.50±3.62AnxietyYesNo13 (40.63%)/10 (41.67%)Lifetime suicidalityNeverInoughts11 (34.38%)Plans4 (12.5%)SuicidalityNoInoughts11 (34.38%)/41 (55.33%)SuicidalityPlansInoughts11 (34.38%)/41 (56.75%)Inoughts11 (34.38%)/41 (55.75%)SuicidalityPlansInoughts11 (34.38%)/41 (55.75%)Inoughts11 (34.38%)/41 (56.75%)Inoughts11 (34.38%)/41 (56.75%)Inoughts11 (34.38%)/41 (56.75%)Inoughts11 (34.38%)/41 (56.75%)Inoughts11 (34.38%)/41 (56.75%)Inoughts11 (34.38%)/41 (56.75%)Inoughts<	Secondary diagnosis		13 (40.63%)
With somatic diagnosis28 (87.5%)Without somatic diagnosis2 (6.26%)No information2 (6.26%)Medication13 (40.63%)Antidepressant and antipsychotic2 (6.25%)Antidepressant and antipsychotic4 (12.5%)Antidepressant and other4 (12.5%)Antidepressant and other4 (12.5%)Other3 (9.38%)Change in last 2 weeks9 (28.13%)No change in last 2 weeks9 (28.13%)Without medication2 (6.26%)CGIImmunMaximum6Mean ± Standard deviation3.16 ± 1.59/3.00 ± 1.41GDS sumImmun1Maximum1AnxietyYes19 (59.38%)/14 (58.33%)No13 (40.63%)/10 (41.67%)11 (34.38%)Lifetime suicidalityNever11 (34.38%)Plans4 (12.5%)11 (34.38%)/16 (57%)SuicidalityNo1 (65.63%)/18 (75%)Plans0 (0)/ 1 (4.17)	Somatic diagnosis		
Without somatic diagnosis2 (6.26%)No information2 (6.26%)Medication13 (40.63%)Antidepressant13 (40.63%)Antidepressant and antipsychotic2 (6.25%)Antidepressant and other4 (12.5%)Antidepressant and other4 (12.5%)Antidepressant, antipsychotic and other4 (12.5%)Other3 (9.38%)Change in last 2 weeks9 (28.13%)No change in last 2 weeks9 (28.13%)Without medication2 (6.26%)CGIGDS sum1Minimum1Maximum6AnxietyYesYes19 (59.38%)/14 (58.33%)No13 (40.63%)/10 (41.67%)Lifetime suicidalityNoNo11 (34.38%)Plans4 (12.5%)SuicidalityNoNo11 (34.38%)/16.67%)Plans0 (0)/1 (4.17)		With somatic diagnosis	28 (87.5%)
No information2 (6.26%)Medication4Antidepressant and antipsychotic2 (6.25%)Antidepressant and antipsychotic4 (12.5%)Antidepressant and other4 (12.5%)Other3 (9.38%)Other3 (9.38%)Change in last 2 weeks9 (28.13%)No change in last 2 weeks21 (65.63%)Without medication6 (26.2%)CGIMaximumMaximum1Maximum3.16±1.59/3.00±1.41GDS sum1/1Maximum1Maximum5.66±3.48/5.50±3.62AnxietyYesNo13 (40.63%)/14 (58.33%)No13 (40.63%)/14 (58.33%)Itfetime suicidalityNeverItoughts11 (34.38%)Plans4 (12.5%)SuicidalityNoNo21 (65.63%)/18 (75%)SuicidalityNoNo10 (41.67%)Itoughts11 (34.38%)/41 (66.7%)Itoughts10 (0) (1 (4.17)		Without somatic diagnosis	2 (6.26%)
MedicationAntidepressant13 (40.63%)Antipsychotic2 (6.25%)Antidepressant and antipsychotic4 (12.5%)Antidepressant and other4 (12.5%)Antidepressant and other4 (12.5%)Antidepressant, antipsychotic and other4 (12.5%)Other3 (9.38%)Other3 (9.38%)Change in last 2 weeks9 (28.13%)No change in last 2 weeks9 (28.13%)Without medication2 (6.66%)CGIMinimumMaximum6Maximum1Maximum1GDS sum1/11Minimum1Maximum1/11Maximum5.66 ± 3.48/5.50 ± 3.62AnxietyYes19 (59.38%)/14 (58.33%)No13 (40.63%)/10 (41.67%)Lifetime suicidalityNever11 (34.38%)Plans4 (12.5%)11 (34.38%)/4 (16.67%)SuicidalityNo21 (65.63%)/18 (75%)No10 (34.38%)/4 (16.67%)10 (34.38%)/4 (16.67%)		No information	2 (6.26%)
Antidepressant13 (40.63%)Antipsychotic2 (6.25%)Antidepressant and antipsychotic4 (12.5%)Antidepressant and other4 (12.5%)Antidepressant, antipsychotic and other4 (12.5%)Other3 (9.38%)Change in last 2 weeks9 (28.13%)No change in last 2 weeks9 (28.13%)Without medication2 (6.26%)CGIGDS sum1Minimum1Maximum6Maximum3.16 ± 1.59/3.00 ± 1.41GDS sum1Maximum12/11Maximum1Maximum1Maximum1Maximum1Maximum1Maximum1/14.38%)Itifetime suicidalityNoNo11 (34.38%)Itifetime suicidalityNoNo11 (34.38%)SuicidalityNoNo21 (65.63%)/18 (75%)SuicidalityNoNo21 (65.63%)/18 (75%)SuicidalityPlansNo21 (65.63%)/18 (75%)Plans0 (0)/1 (4.17)	Medication		
Antipsychotic2 (6.25%)Antidepressant and antipsychotic4 (12.5%)Antidepressant and other4 (12.5%)Antidepressant, antipsychotic and other4 (12.5%)Other3 (9.38%)Change in last 2 weeks9 (28.13%)No change in last 2 weeks2 (6.26%)Without medication2 (6.26%)CGIMinimum1Maximum6Mean ± Standard deviation3 (16 ± 1.59/3.00 ± 1.41GDS sumMinimum1Maximum12/11AnxietyYesNo13 (40.63%)/10 (41.67%)Lifetime suicidalityNeverNo13 (40.63%)/10 (41.67%)SuicidalityNoNo11 (34.38%)Antempts6 (18.75%)SuicidalityNoInoughts11 (34.38%)/4 (16.67%)Plans0 (0)/ 1 (4.17)		Antidepressant	13 (40.63%)
Antidepressant and antipsychotic4 (12.5%)Antidepressant and other4 (12.5%)Antidepressant, antipsychotic and other4 (12.5%)Other3 (9.38%)Other3 (9.38%)Change in last 2 weeks9 (28.13%)No change in last 2 weeks21 (65.63%)Without medication2 (6.26%)CGIMaximum6Mean ± Standard deviation3.16 ± 1.59/3.00 ± 1.41GDS sumMinimum1Maximum12/11Maximum12/11Maximum5.66 ± 3.48/5.50 ± 3.62AnxietyYesNo13 (40.63%)/10 (41.67%)Lifetime suicidalityNeverInoughts11 (34.38%)Plans4 (12.5%)SuicidalityNoInoughts11 (34.38%)/4 (16.67%)Plans0 (0)/ 1 (4.17)		Antipsychotic	2 (6.25%)
Antidepressant and other4 (12.5%)Antidepressant, antipsychotic and other4 (12.5%)Other3 (9.38%)Change in last 2 weeks9 (28.13%)No change in last 2 weeks21 (65.63%)Without medication2 (6.26%)CGIMinimum1Maximum6Mean ± Standard deviation3.16 ± 1.59/3.00 ± 1.41GDS sumGDS sum1Minimum1Maximum5.66 ± 3.48/5.50 ± 3.62AnxietyYesNo13 (40.63%)/10 (41.67%)Lifetime suicidalityNeverNo13 (40.63%)/10 (41.67%)SuicidalityNoSuicidalityNoNo21 (65.63%)/18 (75%)SuicidalityNoPlans11 (34.38%)/4 (16.67%)Floughts11 (34.38%)/4 (16.67%)SuicidalityNoPlans0 (0)/ 1 (4.17)		Antidepressant and antipsychotic	4 (12.5%)
Antidepressant, antipsychotic and other4 (12.5%)Other3 (9.38%)Change in last 2 weeks9 (28.13%)No change in last 2 weeks21 (65.63%)Without medication2 (6.26%)CGI1Maximum6Mean ± Standard deviation3.16 ± 1.59/3.00 ± 1.41GDS sum1Minimum1Maximum12/11Maximum5.66 ± 3.48/5.50 ± 3.62AnxietyYesNo13 (40.63%)/10 (41.67%)Lifetime suicidalityNeverMoughts11 (34.38%)Plans4 (12.5%)SuicidalityNoNo21 (65.63%)/18 (75%)SuicidalityNoPlans0 (0)/ 1 (4.17)		Antidepressant and other	4 (12.5%)
Other3 (9.38%)Change in last 2 weeks9 (28.13%)No change in last 2 weeks21 (65.63%)Without medication2 (6.26%)CGIMinimum1Maximum6Mean ± Standard deviation3.16 ± 1.59/3.00 ± 1.41GDS sumMinimum1Maximum12/11Maximum5.66 ± 3.48/5.50 ± 3.62AnxietyYesYes19 (59.38%)/14 (58.33%)Lifetime suicidalityNoNo13 (40.63%)/10 (41.67%)Lifetime suicidalityNeverPlans4 (12.5%)SuicidalityNoNo21 (65.63%/18 (75%)SuicidalityNoPlans11 (34.38%)/4 (16.67%)Plans0 (0)/ 1 (4.17)		Antidepressant, antipsychotic and other	4 (12.5%)
Change in last 2 weeks 9 (28.13%) No change in last 2 weeks 21 (65.63%) Without medication 2 (6.26%) CGI Minimum 1 Maximum 6 Mean ± Standard deviation 3.16 ± 1.59/3.00 ± 1.41 GDS sum Minimum 1 Maximum 12/11 Maximum 12/11 Mean ± Standard deviation 5.66 ± 3.48/5.50 ± 3.62 Anxiety Yes No 13 (40.63%)/10 (41.67%) Lifetime suicidality Never Inoughts 11 (34.38%) Plans 4 (12.5%) Suicidality No Suicidality No Inoughts 11 (34.38%)/4 (16.67%) Plans 4 (12.5%) Suicidality No No 21 (65.63%)/18 (75%) Plans 0 (0)/ 1 (4.17)		Other	3 (9.38%)
No change in last 2 weeks 21 (65.63%) Without medication 2 (6.26%) CGI I Minimum 1 Maximum 6 Mean ± Standard deviation 3.16±1.59/3.00±1.41 GDS sum I Minimum 1 Maximum 12/11 Maximum 12/11 Mean ± Standard deviation 5.66±3.48/5.50±3.62 Anxiety Yes 19 (59.38%)/14 (58.33%) No 13 (40.63%)/10 (41.67%) Lifetime suicidality Never 11 (34.38%) Plans 4 (12.5%) Attempts 6 (18.75%) Suicidality No 21 (65.63%)/18 (75%) Floughts 11 (34.38%)/4 (16.67%) Plans 0 (0)/ 1 (4.17)		Change in last 2 weeks	9 (28.13%)
Without medication2 (6.26%)CGIMinimum1Maximum60.00000000000000000000000000000000000		No change in last 2 weeks	21 (65.63%)
CGIMinimum1Maximum6Mean ± Standard deviation3.16 ± 1.59/3.00 ± 1.41GDS sum1Minimum1Maximum12/11Mean ± Standard deviation5.66 ± 3.48/5.50 ± 3.62AnxietyYesNo13 (40.63%)/14 (58.33%)Lifetime suicidalityNeverMoughts11 (34.38%)Plans4 (12.5%)SuicidalityNoSuicidalityNoInoughts21 (65.63%)/18 (75%)Thoughts11 (34.38%)/4 (16.67%)Plans0 (0)/ 1 (4.17)		Without medication	2 (6.26%)
Minimum 1 Maximum 6 Mean ± Standard deviation 3.16±1.59/3.00±1.41 GDS sum 1 GDS sum 12/11 Maximum 12/11 Mean ± Standard deviation 5.66±3.48/5.50±3.62 Anxiety Yes No 13 (40.63%)/14 (58.33%) Lifetime suicidality Never Thoughts 11 (34.38%) Plans 4 (12.5%) Suicidality No Suicidality No Intempts 6 (18.75%) Suicidality No Plans 21 (65.63%)/18 (75%) Thoughts 11 (34.38%)/4 (16.67%) Plans 0 (0)/ 1 (4.17)	CGI		
Maximum 6 Mean ± Standard deviation 3.16±1.59/3.00±1.41 GDS sum Minimum 1 Maximum 12/11 Mean ± Standard deviation 5.66±3.48/5.50±3.62 Anxiety Yes 19 (59.38%)/14 (58.33%) Anxiety Yes 13 (40.63%)/10 (41.67%) Lifetime suicidality Never 11 (34.38%) Plans 4 (12.5%) Suicidality No 21 (65.63%)/18 (75%) Suicidality No 21 (65.63%)/18 (75%) Plans 11 (34.38%)/4 (16.67%) Plans 0 (0)/ 1 (4.17)		Minimum	1
$ \begin{array}{llllllllllllllllllllllllllllllllllll$		Maximum	6
GDS sum Minimum 1 Maximum 12/11 Mean ± Standard deviation 5.66 ± 3.48/5.50 ± 3.62 Anxiety Yes 19 (59.38%)/14 (58.33%) No 13 (40.63%)/10 (41.67%) Lifetime suicidality Never 11 (34.38%) Plans 4 (12.5%) Suicidality No 21 (65.63%)/18 (75%) Fuoghts 11 (34.38%)/4 (16.67%) Plans 0 (0)/ 1 (4.17)		Mean \pm Standard deviation	$3.16 \pm 1.59/3.00 \pm 1.41$
Minimum 1 Maximum 12/11 Mean ± Standard deviation 5.66 ± 3.48/5.50 ± 3.62 Anxiety Yes No 13 (40.63%)/10 (41.67%) Lifetime suicidality Never Thoughts 11 (34.38%) Plans 4 (12.5%) Suicidality No Thoughts 11 (34.38%)/4 (16.67%) Plans 0 (0)/ 1 (4.17)	GDS sum		
Maximum 12/11 Mean ± Standard deviation 5.66 ± 3.48/5.50 ± 3.62 Anxiety Yes 19 (59.38%)/14 (58.33%) No 13 (40.63%)/10 (41.67%) Lifetime suicidality Never 11 (34.38%) Thoughts 11 (34.38%) Plans 4 (12.5%) Suicidality No 21 (65.63%)/18 (75%) Thoughts 11 (34.38%)/4 (16.67%) Plans 0 (0)/ 1 (4.17)		Minimum	1
$\begin{array}{llllllllllllllllllllllllllllllllllll$		Maximum	12/11
Anxiety Yes 19 (59.38%)/14 (58.33%) No 13 (40.63%)/10 (41.67%) Lifetime suicidality Never 11 (34.38%) Thoughts 11 (34.38%) Plans 4 (12.5%) Suicidality No 21 (65.63%)/18 (75%) Thoughts 11 (34.38%)/4 (16.67%) Plans 0 (0)/ 1 (4.17)		Mean \pm Standard deviation	$5.66 \pm 3.48 / 5.50 \pm 3.62$
No 13 (40.63%)/10 (41.67%) Lifetime suicidality Never 11 (34.38%) Thoughts 11 (34.38%) Plans 4 (12.5%) Attempts 6 (18.75%) Suicidality No Thoughts 11 (34.38%)/4 (16.67%) Plans 0 (0)/ 1 (4.17)	Anxiety	Yes	19 (59.38%)/14 (58.33%)
Lifetime suicidality Never 11 (34.38%) Thoughts 11 (34.38%) Plans 4 (12.5%) Attempts 6 (18.75%) Suicidality No 21 (65.63%)/18 (75%) Thoughts 11 (34.38%)/4 (16.67%) Plans 0 (0)/ 1 (4.17)		No	13 (40.63%)/10 (41.67%)
Thoughts 11 (34.38%) Plans 4 (12.5%) Attempts 6 (18.75%) Suicidality No 21 (65.63%)/18 (75%) Thoughts 11 (34.38%)/4 (16.67%) Plans 0 (0)/ 1 (4.17)	Lifetime suicidality	Never	11 (34.38%)
Plans 4 (12.5%) Attempts 6 (18.75%) Suicidality No 21 (65.63%)/18 (75%) Thoughts 11 (34.38%)/4 (16.67%) Plans 0 (0)/ 1 (4.17)		Thoughts	11 (34.38%)
Attempts 6 (18.75%) Suicidality No 21 (65.63%)/18 (75%) Thoughts 11 (34.38%)/4 (16.67%) Plans 0 (0)/ 1 (4.17)		Plans	4 (12.5%)
Suicidality No 21 (65.63%)/18 (75%) Thoughts 11 (34.38%)/4 (16.67%) Plans 0 (0)/ 1 (4.17)		Attempts	6 (18.75%)
Thoughts 11 (34.38%)/4 (16.67%) Plans 0 (0)/ 1 (4.17)	Suicidality	No	21 (65.63%)/18 (75%)
Plans 0 (0)/ 1 (4.17)	-	Thoughts	11 (34.38%)/4 (16.67%)
		Plans	0 (0)/ 1 (4.17)
Attempts 0 (0) /1 (4.17)		Attempts	0 (0) /1 (4.17)

port was outpatient treatment in a psychiatric institution (81.3%). At T1, the percentage of people receiving psychosocial support decreased as compared to the six months before T1. This was significant for day clinics (p = .004), outpatient treatment (p = .012), physiotherapy (p = .008) and sports (p < .001). For most psychosocial supportive meas-

Table 3 Pearson cor	relation coefficie	ints between PSI an	d main outcome vari	iables				
How negatively impacted have		GDS-15 sum sco	g	CGI		current suicidality		social contact behavior
you felt in the last two weeks		T1	T2	T1	T2	TI	T2	TI
generally due 7	[1	.384*	. 1	.376*	. 1	.086	I	330
to the COVID- 1 19 pandemic?	[2	Ι	.286	I	.141	I	.226	I
because you 7	L1	.456**	I	.202	I	098	I	357*
belong to the ₁	[72	I	.650**	I	.377	Ι	.346	I
to pre-existing somatic condi- tions?								
because you 7	L1	.210	I	.199	I	.122	I	.081
had symptoms f possibly related to COVID-19?	2	I	n/a	I	n/a	I	n/a	I
because peo-]	L1	053	I	.079	I	.196	I	201
ple close to you had symptoms possibly related to COVID?	2	I	n/a	I	n/a	I	n/a	1
due to difficul- 7	L1	.256	I	.158	I	205	I	401^{*}
ties in receiv- ing planned medical care/ medication?	2	I	.200	I	.252	Į	.173	I
due to difficul- 7	L1	.225	I	.149	I	011	I	327
ties in receiv- ing unplanned medical care/ medication?	2	1	.110	1	.174	1	.031	1

Table 3 (continue	(p							
How negatively impacted have		GDS-15 sum scc	Jre	CGI		current suicidality		social contact behavior
you felt in the last two weeks		T1	T2	T1	T2	T1	T2	T1
due to lock-	T1	.577**	I	.638**	I	.155	I	231
down restric- tions?	T2	I	.341	I	.363	I	.371	I
due to social/	T1	$.400^{*}$	I	.345	I	.184	I	.197
family con- flicts?	T2	Ι	.049	I	.125	I	019	I
due to restric-	T1	.286	I	.327	I	048	I	368*
tions concern- ing leisure and social activities?	T2	I	.550*	I	.461*	I	.343	I
because you	T1	.204	I	.378*	I	.014	I	293
had financial problems due to the COVID- 19 pandemic?	T2	I	.151	I	.238	I	.260	I
due to difficul-	T1	.217	I	.270	I	.139	I	082
ties in getting daily necessi- ties?	T2	I	.039	I	.168	I	.185	1
due to dif-	T1	.293	I	.080	I	272	I	408^{*}
ficulties in shopping not related to daily necessities?	T2	I	.447*	I	.330	I	062	I

How negatively	GDS-15 cun	1 score	UGI		current suic	idality	social contact
impacted have			50		ane mana	(mm)	behavior
you felt in the last two weeks	T1	T2	IT	T2	T1	T2	TI
because peo- T1	.391*	I	.439*	I	.077	I	260
ple close to you T2 were negatively	Ι	.355	I	.337	Ι	.512*	I
impacted by the COVID-19							
pandemic?							
due to the T1	.146	Ι	016	Ι	047	I	056
media coverage T2 of the COVID-	I	.265	I	.066	I	.161	I
19 pandemic?							
because you T1	.387*	Ι	.203	I	.071	I	.253
did not receive T2 enough infor- mation about	I	.275	I	.183	I	.540**	I
the COVID-19 pandemic?							

-obec-2 5 2 2 and not p-values. 111cy appear tively;

T1: n = 32, df = 30; T2: n = 24, df = 22;

n/a = could not be computed because PSI variable was constant

PSI Psychosocial Impact, GDS-15 German Geriatric Depression Scale, CGI Clinical Global Impression



ures, percentage of usage increased (e.g. from 6.3% to 25% for sports) or remained the same from T1 to T2. Only the percentage of people in inpatient treatment fell (18.8% to 8.3%). See Table 4 for an overview of the psychosocial support system of the elderly patients before the pandemic, at T1 and at T2.

A percentage of 53.85% of patients who had been in outpatient treatment before the pandemic could continue their treatment because sessions were held on the phone. There were few other reports of technical solutions to provide continuing treatment, such as receiving materials for arts therapy via mail.

At T2, the number of patients receiving outpatient treatment via phone calls had decreased to n=6, i.e. face-to-face sessions were more frequent (T1: n=3; T2: n=10). McNemar's test revealed that these changes were non-significant.

Concerning the demand for psychosocial support at T1, more than half of patients (53.13%) reported a wish to do sports, followed by arts and occupational therapy (40.63%), physiotherapy (37.50%), treatment in a psychiatric outpatient facility (28.13%) or a day clinic (18.75%) and psychotherapy (15.63%). There were isolated reports (n < 4) of other demands. At T2, demand for an opportunity to do sports was still highest with 29.17%, followed by physiotherapy (25%), psychotherapy (20.83%), and arts or occupational therapy (16.67%). Other reports of demand at T2 were n < 4. The changes in demand were non-significant.

Discussion

To our knowledge, this is the first longitudinal study in elderly psychiatric patients reporting a significant association between psychosocial burden and both depression and severity of illness as well as significant differences in PSI regarding social contact

Six $(n = \frac{n}{2})$ Psychosocial support $n (\%$ Any support 31 (x months before T1		
Psychosocial support n (% Anv support 31 (=32)	T1 (April/ May 2020) $(n=32)$	T2 (August 2020) (n=24)
Any support 31 ((%)	(%) u	(2) u
	(96.9%)	29 (90.6%)	24 (100%)
Inpatient treatment 8 (2	(25%)	6(18.8%)	2(8.3%)
Day clinic 9 (2	(28.1%)	0*	1 (4.2%)
Outpatient treatment 26 (5 (81.3%)	17~(53.1%)*	16(66.7%)
Psychotherapy 2 (6	(6.3%)	1 (3.1%)	2 (8.3%)
1 (3 Rehabilitation	(3.1%)	0	0
Psychiatric nursing service 0		1 (3.1%)	1 (4.2%)
Nursing service 3 (9	(9.4%)	2 (6.3%)	4 (16.7%)
Physiotherapy 17 (1 (53.1%)	5 (15.6%)*	6 (25%)
Art/occupational therapy 12 (! (37.5%)	7 (21.9%)	8 (33.3%)
Group therapy 3 (9	(9.4%)	2 (6.3%)	1(4.2%)
Self-help-group 3 (9	(9.4%)	1(3.1%)	1 (4.2%)
Sports 19 () (59.4%)	$2 (6.3\%)^{*}$	6 (25%)
Social counselling 5 (1	(15.6%)	3 (9.7%)	3 12.5%)
Social support, e.g. case work 1 (3	(3.1%)	1 (3.1%)	1(4.2%)
Other 6 (1	(18.8%)	2 (6.3%)	4 (16.7%)

during the COVID-19 pandemic. The findings may provide information for policy makers in the current and potential future crises on how to best support this population.

Psychosocial Impact

A negative PSI of the pandemic was reported by most participants which is in line with effects of the pandemic on the general population, as shown by a recent meta-analysis [38].

Patients with higher symptom burden of depression reported a more negative PSI of the pandemic. More specifically, at T1, patients with higher depression scores indicated a more severe PSI. Moreover, at T1, patients who were rated to be more severely ill were also more negatively impacted by the pandemic. Severity of illness showed a significant positive correlation with PSI due to financial issues during the pandemic.

One possible explanation is that depression in the elderly is linked to lower resilience [39], i.e. a decreased ability to protect one's mental health when confronted with stressors [40]. Thus, patients with depression may be less able to handle isolation, uncertainty and other demands during the pandemic. A significant difference between psychiatric patients and healthy controls during the COVID-19 pandemic and higher levels of PTSD, anxiety, depression, stress and insomnia had been shown [41].

In addition, patients in a depressed state may be biased towards a more negative selfevaluation of their current situation than during a non-depressive condition.

We were able to verify the impact of the pandemic situation on patients with psychiatric conditions and further show a link between illness severity and PSI. This outlines the importance of offering effective psychosocial support to elderly patients with preexisting psychiatric conditions. It should be noted however that results could also be explained by a negative bias in self-reports among patients suffering from depression.

Social Contact

Significant inverse correlations were found between social contact behavior and negative PSI: people with more social contact felt less impacted by being member of a risk group, by difficulties with medical care access, by restrictions in leisure, social activities and consumption.

It has previously been shown that social contact can reduce psychosocial distress during a pandemic [42]. This is critical, given that containment measures such as social distancing reduce social contacts. These measures can cause distress and traumatization [12].

Surprisingly, patients with close social contact had a significant higher general PSI than patients with rare social contact at T1 and general PSI values in those with regular social contact were lowest. Elderly people may suffer from loneliness or non-integrated social networks [43]. Thus, patients being used to cultivating social contact and closeness to dependents may therefore be more severely affected by reduced contact and altered existing relationships/routines.

Changes between T1 and T2

T2 was set in August 2020 when the Robert Koch Institute described the development of the 7-day incidence as "concerning" [44]. During this time, the number of new reported daily SARS-CoV-2 infections reached over 2000 cases for the first time since end of April. While no severe lockdown measures were in place at that point, certain pandemic-related restrictions were ongoing, such as the recommendation to wear a mask and socially distance. We did not find a significant reduction in general PSI nor in main mental health outcome variables between T1 and T2. Indeed, the high number of drop-outs at T2 (n = 12) has to be taken into consideration where several patients reported to be too unstable to continue participation.

To some extent, PSI may have decreased at T2 considering lower infection numbers compared to T1 as well as the patient's adaption to the pandemic situation and containment measures. Decreasing PSI values due to the restriction themselves support this statement – supposedly due to habituation and an establishment of helping systems.

Alternatively, PSI may have increased due to partly ongoing restrictions and re-arising infection numbers in August 2020. Patients may have been impacted by expectation of reinstallation and intensification of policies, leading to a deterioration of PSI as compared to T1. This explanation seems plausible as many patients stated that they were afraid of a "second wave" and worried about new restrictions and "recklessness" of people who did not adhere to regulations.

The missing difference between the two timepoints may suggest antagonizing effects of both refuted hypotheses.

A previous study during the COVID-19 outbreak also revealed no significant change in PSI one month after the first survey. The mean scores for depression, anxiety and stress also did not change [45]. Even though data was collected in different phases of the COVID-19 pandemic, PSI appears to not remarkably change over a period of a few months. This may be caused by a fundamental feeling of uncertainty and even be strengthened considering the older age of participants in the presented study with more critical needs for consistency and lack thereof during the pandemic.

Follow-up studies after complete withdrawal of containment measures are needed to assess differences in PSI during and after the ongoing pandemic.

At T1, suicidal thoughts were more frequent than at T2, whereas suicidal plans and attempts were only reported at T2. Suicidal ideation in the context of containment measures has been described previously and is likely to be linked to the pandemic situation [46, 47].

Psychosocial Support

Psychosocial support decreased due to the pandemic. This was reflected in the reported demand for supportive measures: a majority of patients wished to do sports again and many reported a demand for arts and occupational therapy, physiotherapy, treatment in an outpatient facility or day clinic and psychotherapy. While the psychosocial support system had grown at T2, there was still a high demand for sports, physiotherapy, psychotherapy and arts or occupational therapy. Being a study conducted in current and former patients of a psychiatric hospital, these results portray a group of people dependent on psychosocial support due to pre-existing psychiatric illnesses. However,

the results also show that elderly patients have diverse interests and are open to receive help and support.

During the pandemic, programs for psychosocial crisis intervention have evolved, also using remote strategies such as telephone or internet [48]. Moreover, multidisciplinary teams have been built in order to improve mental health of people being psychosocially affected during the pandemic [49]. This was also reflected in our sample: many patients were able to continue outpatient treatment via phone calls. However, a positive effect of information and communication technologies on loneliness in elderly people could not yet be shown [50], revealing the complexity of improvement by modern communication tools in this group even if they are available.

Limitations

Several limitations have to be considered in interpretation of our results.

While telephone interviews may enable patients to talk more freely, they also carry the risk of misunderstandings. Moreover, only retrospective questioning was conducted concerning the time before the pandemic, possibly reducing accuracy of reports.

Further, inclusion of patients may have been dependent on the ability to participate in interviews. Patients with comparatively better psychosocial well-being may be over-represented. In line with challenges of recruiting higher aged patients and the rapidly evolving COVID-19 crisis at T1, the presented study consists of a relatively small cohort. This may explain why apparent changes in psychosocial support were non-significant.

Overall, due to the small sample size and the high number of drop-outs at T2, statistical power is limited. Hence, the study has to be considered as a pilot study. Future studies with a larger number of patients in the context of patients and controls are needed to re-evaluate and confirm the presented results.

Generally, as the COVID-19 crisis is a rapidly evolving scientific issue, the discussed literature is biased towards studies being published rather at the beginning of the pandemic. Cited literature may originate primarily from countries where the pandemic started to spread, possibly reducing generalizability.

Conclusion

In summary, our study in elderly patients with psychiatric disorders found patients with depression, higher psychiatric illness severity and less social contact to be more affected by the current COVID-19 pandemic. Utilization of psychosocial support decreased during the pandemic despite a high demand for support reported by elderly patients.

These results highlight the challenges for elderly psychiatric patients during the pandemic. In addition to proneness to somatic illness and severe sequelae of SARS-CoV-2 infection, these individuals are more likely affected by an impaired psychosocial situation.

Patients' needs should be considered in political decisions and clinical management to ensure well-being of this patient group throughout this ongoing as well as future pandemics.

Acknowledgments The authors would like to thank the participants. We furthermore would like to thank Joram Kluge, Theresa Behmer and Mike Klar for assistance with the telephone interviews.

Authors' Contributions M. Seethaler and S. Just contributed equally to the study and share first authorship. Study concept and design: M. Seethaler, S. Just, P. Stötzner, F. Bermpohl, E. Brandl. Acquisition, analysis and interpretation of data: M. Seethaler, S. Just. Statistical analysis: M. Seethaler, S. Just.Drafting of the manuscript: M. Seethaler, S. Just.Critical revision of the manuscript: M. Seethaler, S. Just., P. Stötzner, F. Bermpohl, E. Brandl.Supervision: F. Bermpohl, E. Brandl.All authors read and approved the final manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL.

Data Availability M. Seethaler and S. Just had full access to all of the data in the study and take responsibility for the accuracy of the data analysis and the integrity of the data.

Code Availability Not applicable.

Declarations

Ethics Approval The study was approved by the local ethics committee and followed the principles of the Declaration of Helsinki.

Consent to Participate All participants provided written consent to participate in the study.

Consent for Publication All participants provided written consent for publication of the data.

Ethical Publication We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Conflict of Interest EJB has received speaker fees from Servier and Medice.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

- Johns Hopkins University. Johns Hopkins Coronavirus Resource Center 2020. https://coronavirus.jhu. edu/map.html.
- Center for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) 2020. https://www. cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html#hospitalizations.
- Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;3099:1–9. https://doi.org/ 10.1016/s1473-3099(20)30243-7.
- Abate SM, Ali SA, Mantfardo B, Basu B. Rate of intensive care unit admission and outcomes among patients with coronavirus: a systematic review and meta-analysis. PLoS One. 2020;15:1–19. https:// doi.org/10.1371/journal.pone.0235653.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3.
- Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai FS, et al. Coronavirus disease 2019 case surveillance - United States, January 22-may 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:759–65. https://doi.org/10.15585/mmwr.mm6924e2.
- Grantz KH, Rane MS, Salje H, Glass GE, Schachterle SE, Cummings DAT. Disparities in influenza mortality and transmission related to sociodemographic factors within Chicago in the pandemic of 1918. Proc Natl Acad Sci U S A. 2016;113:13839–44. https://doi.org/10.1073/pnas.1612838113.

- Hutchins SS, Fiscella K, Levine RS, Ompad DC, McDonald M. Protection of racial/ethnic minority populations during an influenza pandemic. Am J Public Health. 2009;99:261–70. https://doi.org/10. 2105/AJPH.2009.161505.
- Betancourt TS, Brennan RT, Vinck P, VanderWeele TJ, Spencer-Walters D, Jeong J, et al. Associations between mental health and Ebola-related health behaviors: a regionally representative cross-sectional survey in post-conflict Sierra Leone. PLoS Med. 2016;13:1–15. https://doi.org/10.1371/journal.pmed. 1002073.
- Al Knawy BA, Al-Kadri HMF, Elbarbary M, Arabi Y, Balkhy HH, Clark A. Perceptions of postoutbreak management by management and healthcare workers of a Middle East respiratory syndrome outbreak in a tertiary care hospital: a qualitative study. BMJ Open. 2019;9:1–9. https://doi.org/10.1136/ bmjopen-2017-017476.
- Nickell LA, Crighton EJ, Tracy CS, Al-Enazy H, Bolaji Y, Hanjrah S, et al. Psychosocial effects of SARS on hospital staff: survey of a large tertiary care institution. Cmaj. 2004;170:793–8. https://doi. org/10.1503/cmaj.1031077.
- 12. Sprang G, Silman M. Posttraumatic stress disorder in parents and youth after health-related disasters. Disaster Med Public Heal Prep. 2013;7:105–10. https://doi.org/10.1017/dmp.2013.22.
- 13. WHO. Pandemic (H1N1) 2009 update 112 2010. https://www.who.int/csr/don/2010_08_06/en/.
- WHO. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 2003. https://www.who.int/publications/m/item/summary-of-probable-sars-cases-with-onset-of-illnessfrom-1-november-2002-to-31-july-2003.
- Marroquín B, Vine V, Morgan R. Mental health during the COVID-19 pandemic: effects of stay-athome policies, social distancing behavior, and social resources. Psychiatry Res. 2020;113419. https:// doi.org/10.1016/j.psychres.2020.113419.
- Wang C, Pan R, Wan X, Tan Y, Xu L, Ho CS, et al. Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. Int J Environ Res Public Health. 2020;17. https://doi.org/10.3390/ijerph1705 1729.
- Qiu J, Shen B, Zhao M, Wang Z, Xie B, Xu Y. A nationwide survey of psychological distress among Chinese people in the COVID-19 epidemic: implications and policy recommendations. Gen Psychiatry. 2020;33:19–21. https://doi.org/10.1136/gpsych-2020-100213.
- Luo M, Guo L, Yu M, Wang H. The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public – a systematic review and meta-analysis. Psychiatry Res. 2019;2020:113190. https://doi.org/10.1016/j.psychres.2020.113190.
- Fofana NK, Latif F, Sarfraz S, Bilal, Bashir MF, Komal B. Fear and agony of the pandemic leading to stress and mental illness: An emerging crisis in the novel coronavirus (COVID-19) outbreak. Psychiatry Res 2020;291. https://doi.org/10.1016/j.psychres.2020.113230.
- Mo Y, Deng L, Zhang L, Lang Q, Liao C, Wang N, et al. Work stress among Chinese nurses to support Wuhan in fighting against COVID-19 epidemic. J Nurs Manag. 2020. https://doi.org/10.1111/jonm. 13014.
- Kang L, Ma S, Chen M, Yang J, Wang Y, Li R, et al. Impact on mental health and perceptions of psychological care among medical and nursing staff in Wuhan during the 2019 novel coronavirus disease outbreak: A cross-sectional study. Brain Behav Immun 2020:1–7. https://doi.org/10.1016/j.bbi.2020. 03.028.
- Tan B, Chew N, Lee G, Jing M, Yeo L, Zhang K, et al. Psychological impact of the COVID-19 pandemic on health Care Workers in Singapore. Ann Intern Med. 2020;16:2019–21. https://doi.org/10. 7326/M20-1083.
- Li Z, Ge J, Yang M, Feng J, Qiao M, Jiang R, et al. Vicarious traumatization in the general public, members, and non-members of medical teams aiding in COVID-19 control. Brain Behav Immun 2020:0–1. https://doi.org/10.1016/j.bbi.2020.03.007.
- Krendl AC, Perry BL. The Impact of Sheltering in Place During the COVID-19 Pandemic on Older Adults' Social and Mental Well-Being. Journals Gerontol Ser B 2020;XX:1–6. https://doi.org/10.1093/ geronb/gbaa110.
- Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA - J Am Med Assoc. 2019;2020:2019–20. https://doi.org/10.1001/jama. 2020.4683.
- Wilder-Smith A, Freedman DO. Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak. J Travel Med. 2020;27:1–4. https://doi.org/10.1093/jtm/taaa020.

- Fulford KWM, Howse K. Ethics of research with psychiatric patients: principles, problems and the primary responsibilities of researchers. J Med Ethics. 1993;19:85–91. https://doi.org/10.1136/jme.19.2. 85.
- Bundesregierung. Telefonschaltkonferenz der Bundeskanzlerin mit den Regierungschefinnen und Regierungschefs der Länder am 06. Mai 2020 2020. https://www.bundesregierung.de/breg-de/themen/ coronavirus/telefonschaltkonferenz-der-bundeskanzlerin-mit-den-regierungschefinnen-undregierungschefs-der-laender-am-06-mai-2020-1750988.
- 29. Kubicek H. Leitfaden Digitale Kompetenzen für ältere Menschen. Stift Digit Chancen. 2018.
- Perissinotto CM, Stijacic Cenzer I, Covinsky KE. Loneliness in older persons: a predictor of functional decline and death. Arch Intern Med. 2012. https://doi.org/10.1001/archinternmed.2012.1993.
- Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982. https://doi.org/10. 1016/0022-3956(82)90033-4.
- Allgaier AK, Kramer D, Mergl R, Fejtkova S, Hegerl U. Validität der Geriatrischen Depressionsskala bei Altenheimbewohnern: Vergleich von GDS-15, GDS-8 und GDS-4. Psychiatr Prax. 2011. https:// doi.org/10.1055/s-0030-1266105.
- Wancata J, Alexandrowicz R, Marquart B, Weiss M, Friedrich F. The criterion validity of the geriatric depression scale: a systematic review. Acta Psychiatr Scand. 2006;114:398–410. https://doi.org/10. 1111/j.1600-0447.2006.00888.x.
- Wild B, Herzog W, Schellberg D, Lechner S, Niehoff D, Brenner H, et al. Association between the prevalence of depression and age in a large representative German sample of people aged 53 to 80years. Int J Geriatr Psychiatry. 2012;27:375–81. https://doi.org/10.1002/gps.2728.
- Weintraub D, Oehlberg KA, Katz IR, Stern MB. Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. Am J Geriatr Psychiatry. 2006. https://doi.org/10.1097/01.JGP.0000192488.66049.4b.
- Bobon D, Ansseau M. The AMDP-system in clinical psychopharmacology. Pharmacopsychiatry. 1986. https://doi.org/10.1055/s-2007-1017153.
- 37. Guy W. CGI Clinical Global Impressions. ECDEU Assess Man. 1976.
- Henssler J, Stock F, van Bohemen J, Walter H, Heinz A, Brandt L. Mental health effects of infection containment strategies: quarantine and isolation-a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2020. https://doi.org/10.1007/s00406-020-01196-x.
- Mehta M, Whyte E, Lenze E, Hardy S, Roumani Y, Subashan P, et al. Depressive symptoms in late life: associations with apathy, resilience and disability vary between young-old and old-old. Int J Geriatr Psychiatry. 2008. https://doi.org/10.1002/gps.1868.
- Davydov DM, Stewart R, Ritchie K, Chaudieu I. Resilience and mental health. Clin Psychol Rev. 2010. https://doi.org/10.1016/j.cpr.2010.03.003.
- Hao F, Tan W, Jiang L, Zhang L, Zhao X, Zou Y, et al. Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown ? A case-control study with service and research implications for immunopsychiatry. Brain Behav Immun. 2020;87:100–6. https://doi.org/10. 1016/j.bbi.2020.04.069.
- Petzold MB, Bendau A, Plag J, Pyrkosch L, Mascarell Maricic L, Betzler F, et al. Risk, resilience, psychological distress, and anxiety at the beginning of the COVID-19 pandemic in Germany. Brain Behav. 2020;10:1–10. https://doi.org/10.1002/brb3.1745.
- Golden J, Conroy RM, Bruce I, Denihan A, Greene E, Kirby M, et al. Loneliness, social support networks, mood and wellbeing in community-dwelling elderly. Int J Geriatr Psychiatry. 2009;24:694–700. https://doi.org/10.1002/gps.2181.
- 44. (RKI) R-K-I. Coronavirus Disease 2019 Daily Situation Report of the Robert Koch Institute Epidemiological Situation in Germany. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/ Situationsberichte/2020-08-31-en.pdf?__blob=publicationFile
- 45. Wang C, Pan R, Wan X, Tan Y, Xu L, Mcintyre RS, et al. A longitudinal study on the mental health of general population during the COVID-19 epidemic in China. Brain Behav Immun. 2020;87:40–8. https://doi.org/10.1016/j.bbi.2020.04.028.
- 46. Every-Palmer S, Jenkins M, Gendall P, Hoek J, Beaglehole B, Bell C, et al. Psychological distress, anxiety, family violence, suicidality, and wellbeing in New Zealand during the COVID-19 lockdown: a cross-sectional study. PLoS One. 2020;15:1–19. https://doi.org/10.1371/journal.pone.0241658.
- Gunnell D, Appleby L, Arensman E, Hawton K, John A, Kapur N, et al. Suicide risk and prevention during the COVID-19 pandemic. Lancet Psychiatry. 2020. https://doi.org/10.1016/S2215-0366(20) 30171-1.

- Jiang X, Deng L, Zhu Y, Ji H, Tao L, Liu L, et al. Psychological crisis intervention during the outbreak period of new coronavirus pneumonia from experience in Shanghai. Psychiatry Res. 2020. https://doi. org/10.1016/j.psychres.2020.112903.
- Hyun J, You S, Sohn S, Kim SJ, Bae J, Baik M, et al. Psychosocial support during the COVID-19 outbreak in Korea: activities of multidisciplinary mental health professionals. J Korean Med Sci. 2020;35:1–13. https://doi.org/10.3346/JKMS.2020.35.E211.
- Chen YRR, Schulz PJ. The effect of information communication technology interventions on reducing social isolation in the elderly: a systematic review. J Med Internet Res. 2016;18:e18. https://doi.org/10. 2196/jmir.4596.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Magdalena Seethaler, MD is a second year psychiatry resident at the Psychiatric University Clinic at St. Hedwig Hospital, Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin. After receiving her MD degree from Technical University Munich she worked as a research trainee at the Psychiatry Neuroimaging Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, USA.

Sandra Just, M.Sc. is a clinical psychologist at the Psychiatric University Clinic at St. Hedwig Hospital, Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin. She completed two Master's degrees at King's College London and Free University of Berlin. She is a psychological psychotherapist with expertise in Behavioural Therapy.

Philip Stötzner, MD is a fifth year psychiatry resident at the Psychiatric University Clinic at St. Hedwig Hospital, Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin. He received his MD at the Charité and did his doctorate in the field of pain research. He currently does advanced training in psychoanalysis.

Felix Bermpohl, MD is head of the Psychiatric University Clinic at St. Hedwig Hospital, Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin. He has expertise in studying emotion, reward, social cognition, and cognitive control in patients with affective disorders and patients with substance use disorders. His methodological repertoire includes clinical assessment, neurocognitive testing, endocrine, genetic and epigenetic investigations, as well as functional magnetic resonance.

Eva Janina Brandl, MD is senior physician at the geriatric psychiatry centre of Psychiatric University Clinic at St. Hedwig Hospital, Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin. After completing her doctoral thesis on genetic influences on antipsychotic induced weight increase at Charité she worked as a research fellow at the Centre for Addiction and Mental Health in Toronto, Canada. Afterwards, she continued her scientific work at Charité supported by the Clinican Scientist Program of Berlin Institute of Health and qualified as a university lecturer in genetic influences on the respond and side effects of psychopharmaceuticals. Besides her expertise in pharmacogenetics, she focuses on healthcare research. She leads the research group for clinical geriatric psychiatry and psychotherapy.